Genen­tech part­ners with cash-strapped Sang­amo on epi­ge­net­ic Alzheimer’s ther­a­py

An ex­per­i­men­tal Alzheimer’s drug and its de­sign­er are get­ting a sec­ond chance.
On Tues­day, Sang­amo an­nounced it had part­nered with Genen­tech to de­vel­op an epi­ge­net­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER